A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer

NCT06072781 · readout in 788 d

Sponsored by Verastem, Inc. (industry) · VSTM — their whole pipeline →. With GOG Foundation, European Network of Gynaecological Oncological Trial Groups (ENGOT), Australia New Zealand Gynaecological Oncology Group, Korean Gynecologic Oncology Group.

Phase

Phase 3

Status

Recruiting

Study type

Interventional

Design

Randomized · None · Treatment

Enrollment

270estimated

Sites

106

Countries

Australia, Belgium, Canada +13

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2024-03-18

actual

When the study began enrolling

Primary completion

2028-10-15

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

2031-02-09

estimated

The whole study's end, after follow-up

First posted

2023-10-10

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-08-14

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

Low Grade Serous Ovarian Cancer

Interventions

Drug: avutometinib — also filed as avutometinib (VS-6766)
Drug: Defactinib — also filed as defactinib (VS-6063)
Drug: Pegylated liposomal doxorubicin — also filed as Caelyx, Doxil, Lipodox
Drug: Paclitaxel — also filed as Nov-Onxol, Onxol, Navaplus, Taxol
Drug: Letrozole — also filed as Femara
Drug: Anastrozole — also filed as Arimidex

Primary outcome

what the primary-completion date above is the date OF

Progression Free Survival (PFS) per blinded independent central review (BICR)

measured Up to 24 months

Publications

PMID 41384753 — linked by the registry
PMID 40644648 — linked by the registry
PMID 39375168 — linked by the registry

Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.

Permalink · VSTM's whole pipeline · Catalyst calendar · Every registered study · What changed